Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of FLOFOXIRI plus bevacizumab for liver and/or lung metastases from colorectal carcinoma
2007-004535-33Phase 2Terminated
- Sponsor
- Heidelberg University Hospital
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in colorectal cancer (CRC), sponsored by Heidelberg University Hospital. Primary endpoint: Surgically complete resectability (S-CR, R0 resection). Started Mar 2009; status: terminated.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-004535-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004535-33.